Trial Profile
A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Marizomib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms MIRAGE
- 25 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 23 May 2023 Planned End Date changed from 1 Jul 2023 to 30 Jun 2023.
- 19 Nov 2022 This trial has been completed in Austria (Global end date 22 Aug 2022) according to European Clinical Trials Database record